Sotuletinib dihydrochloride

Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM. It promotes apoptosis in tumor cells and significantly restricts tumor growth in murine models, proving useful in cancer and amyotrophic lateral sclerosis (ALS) studies [1].